DnB Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
Other funds holding RXRX
AIM
MCMU
DnB Asset Management's RXRX Position: Q2 2026 in Review
DnB Asset Management increased its Recursion Pharmaceuticals (RXRX) stake by 2,141% in Q2 2026, buying an estimated $2.18M and bringing the position to 685,901 shares worth $2.52M. The position accounts for 0.01% of the portfolio, ranked #580.
DnB Asset Management first reported a position in RXRX in Q3 2022 and has held it in 7 quarters since. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.
- DnB Asset Management held 685,901 shares of Recursion Pharmaceuticals worth $2.52M as of Q2 2026.
- DnB Asset Management bought 655,294 Recursion Pharmaceuticals shares in Q2 2026, an estimated $2.18M.
- Recursion Pharmaceuticals made up 0.01% of DnB Asset Management's portfolio in Q2 2026, its #580 holding.
- DnB Asset Management first reported a position in Recursion Pharmaceuticals in Q3 2022 and has held it in 7 quarters since.
- 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.
Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.